GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » EBITDA

Adicon Holdings (HKSE:09860) EBITDA : HK$706 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings EBITDA?

Adicon Holdings's EBITDA for the six months ended in Dec. 2023 was HK$0 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$706 Mil.

During the past 12 months, the average EBITDA Growth Rate of Adicon Holdings was -45.20% per year. During the past 3 years, the average EBITDA Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 4 years, the highest 3-Year average EBITDA Growth Rate of Adicon Holdings was 4.20% per year. The lowest was 4.20% per year. And the median was 4.20% per year.

Adicon Holdings's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.98.

During the past 12 months, the average EBITDA per Share Growth Rate of Adicon Holdings was -44.60% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of Adicon Holdings was 4.50% per year. The lowest was 4.50% per year. And the median was 4.50% per year.


Adicon Holdings EBITDA Historical Data

The historical data trend for Adicon Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicon Holdings EBITDA Chart

Adicon Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA
582.77 699.69 1,203.37 659.69

Adicon Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Get a 7-Day Free Trial - 522.67 489.45 216.11 -

Competitive Comparison of Adicon Holdings's EBITDA

For the Diagnostics & Research subindustry, Adicon Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicon Holdings's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adicon Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adicon Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Adicon Holdings's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Adicon Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Adicon Holdings's EBITDA was HK$660 Mil.

Adicon Holdings's EBITDA for the quarter that ended in Dec. 2023 is calculated as

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$706 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Adicon Holdings  (HKSE:09860) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Adicon Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicon Holdings (HKSE:09860) Business Description

Traded in Other Exchanges
Address
No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN
Adicon Holdings Ltd is one of the top three independent clinical laboratory or ICL, service providers in China. The company offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China. The high quality of its services is backed by its strong performance in terms of international accreditation and comprehensive testing menu. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests. It has three major service platforms. Among them, the inspection service platform consists of clinical, pathology, reproductive genetic, genetic, and mass spectrometry laboratories.
Executives
Cap V General Partner, L.p. 2201 Interest of corporation controlled by you
Cap V, L.l.c. 2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c. 2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c. 2201 Interest of corporation controlled by you
Pearl Group Limited 2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p. 2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p. 2201 Interest of corporation controlled by you
The Carlyle Group Inc. 2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited 2301 Trustee
Ingenuity Capital Holdings Limited 2201 Interest of corporation controlled by you
Corelink Group Limited

Adicon Holdings (HKSE:09860) Headlines

No Headlines